Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors

Kai Cheng Hsu, Hui Chen Hung, Jim Tong Horng, Ming Yu Fang, Chun Yu Chang, Ling Ting Li, I. Jung Chen, Yun Chu Chen, Ding Li Chou, Chun Wei Chang, Hsing Pang Hsieh, Jinn Moon Yang, John T A Hsu

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Infection with influenza virus is a major public health problem, causing serious illness and death each year. Emergence of drug-resistant influenza virus strains limits the effectiveness of drug treatment. Importantly, a dual H275Y/I223R mutation detected in the pandemic influenza A 2009 virus strain results in multidrug resistance to current neuraminidase (NA) drugs. Therefore, discovery of new agents for treating multiple drug-resistant (MDR) influenza virus infections is important. Here, we propose a parallel screening strategy that simultaneously screens wild-type (WT) and MDR NAs, and identifies inhibitors matching the subsite characteristics of both NA-binding sites. These may maintain their potency when drug-resistant mutations arise. Initially, we analyzed the subsite of the dual H275Y/I223R NA mutant. Analysis of the site-moiety maps of NA protein structures show that the mutant subsite has a relatively small volume and is highly polar compared with the WT subsite. Moreover, the mutant subsite has a high preference for forming hydrogen-bonding interactions with polar moieties. These changes may drive multidrug resistance. Using this strategy, we identified a new inhibitor, Remazol Brilliant Blue R (RB19, an anthraquinone dye), which inhibited WT NA and MDR NA with IC50 values of 3.4 and 4.5 μM, respectively. RB19 comprises a rigid core scaffold and a flexible chain with a large polar moiety. The former interacts with highly conserved residues, decreasing the probability of resistance. The latter forms van der Waals contacts with the WT subsite and yields hydrogen bonds with the mutant subsite by switching the orientation of its flexible side chain. Both scaffolds of RB19 are good starting points for lead optimization. The results reveal a parallel screening strategy for identifying resistance mechanisms and discovering anti-resistance neuraminidase inhibitors. We believe that this strategy may be applied to other diseases with high mutation rates, such as cancer and human immunodeficiency virus type 1.

Original languageEnglish
Article numbere56704
JournalPLoS One
Volume8
Issue number2
DOIs
Publication statusPublished - Feb 20 2013
Externally publishedYes

Fingerprint

sialidase
Neuraminidase
Screening
Viruses
screening
drugs
Pharmaceutical Preparations
Orthomyxoviridae
mutants
multiple drug resistance
Multiple Drug Resistance
mutation
Scaffolds
Hydrogen bonds
Drug therapy
Anthraquinones
Mutation
hydrogen bonding
anthraquinones
Influenza A virus

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hsu, K. C., Hung, H. C., Horng, J. T., Fang, M. Y., Chang, C. Y., Li, L. T., ... Hsu, J. T. A. (2013). Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors. PLoS One, 8(2), [e56704]. https://doi.org/10.1371/journal.pone.0056704

Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors. / Hsu, Kai Cheng; Hung, Hui Chen; Horng, Jim Tong; Fang, Ming Yu; Chang, Chun Yu; Li, Ling Ting; Chen, I. Jung; Chen, Yun Chu; Chou, Ding Li; Chang, Chun Wei; Hsieh, Hsing Pang; Yang, Jinn Moon; Hsu, John T A.

In: PLoS One, Vol. 8, No. 2, e56704, 20.02.2013.

Research output: Contribution to journalArticle

Hsu, KC, Hung, HC, Horng, JT, Fang, MY, Chang, CY, Li, LT, Chen, IJ, Chen, YC, Chou, DL, Chang, CW, Hsieh, HP, Yang, JM & Hsu, JTA 2013, 'Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors', PLoS One, vol. 8, no. 2, e56704. https://doi.org/10.1371/journal.pone.0056704
Hsu, Kai Cheng ; Hung, Hui Chen ; Horng, Jim Tong ; Fang, Ming Yu ; Chang, Chun Yu ; Li, Ling Ting ; Chen, I. Jung ; Chen, Yun Chu ; Chou, Ding Li ; Chang, Chun Wei ; Hsieh, Hsing Pang ; Yang, Jinn Moon ; Hsu, John T A. / Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors. In: PLoS One. 2013 ; Vol. 8, No. 2.
@article{e2e382394f6845af95d24bfb44a89ab7,
title = "Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors",
abstract = "Infection with influenza virus is a major public health problem, causing serious illness and death each year. Emergence of drug-resistant influenza virus strains limits the effectiveness of drug treatment. Importantly, a dual H275Y/I223R mutation detected in the pandemic influenza A 2009 virus strain results in multidrug resistance to current neuraminidase (NA) drugs. Therefore, discovery of new agents for treating multiple drug-resistant (MDR) influenza virus infections is important. Here, we propose a parallel screening strategy that simultaneously screens wild-type (WT) and MDR NAs, and identifies inhibitors matching the subsite characteristics of both NA-binding sites. These may maintain their potency when drug-resistant mutations arise. Initially, we analyzed the subsite of the dual H275Y/I223R NA mutant. Analysis of the site-moiety maps of NA protein structures show that the mutant subsite has a relatively small volume and is highly polar compared with the WT subsite. Moreover, the mutant subsite has a high preference for forming hydrogen-bonding interactions with polar moieties. These changes may drive multidrug resistance. Using this strategy, we identified a new inhibitor, Remazol Brilliant Blue R (RB19, an anthraquinone dye), which inhibited WT NA and MDR NA with IC50 values of 3.4 and 4.5 μM, respectively. RB19 comprises a rigid core scaffold and a flexible chain with a large polar moiety. The former interacts with highly conserved residues, decreasing the probability of resistance. The latter forms van der Waals contacts with the WT subsite and yields hydrogen bonds with the mutant subsite by switching the orientation of its flexible side chain. Both scaffolds of RB19 are good starting points for lead optimization. The results reveal a parallel screening strategy for identifying resistance mechanisms and discovering anti-resistance neuraminidase inhibitors. We believe that this strategy may be applied to other diseases with high mutation rates, such as cancer and human immunodeficiency virus type 1.",
author = "Hsu, {Kai Cheng} and Hung, {Hui Chen} and Horng, {Jim Tong} and Fang, {Ming Yu} and Chang, {Chun Yu} and Li, {Ling Ting} and Chen, {I. Jung} and Chen, {Yun Chu} and Chou, {Ding Li} and Chang, {Chun Wei} and Hsieh, {Hsing Pang} and Yang, {Jinn Moon} and Hsu, {John T A}",
year = "2013",
month = "2",
day = "20",
doi = "10.1371/journal.pone.0056704",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors

AU - Hsu, Kai Cheng

AU - Hung, Hui Chen

AU - Horng, Jim Tong

AU - Fang, Ming Yu

AU - Chang, Chun Yu

AU - Li, Ling Ting

AU - Chen, I. Jung

AU - Chen, Yun Chu

AU - Chou, Ding Li

AU - Chang, Chun Wei

AU - Hsieh, Hsing Pang

AU - Yang, Jinn Moon

AU - Hsu, John T A

PY - 2013/2/20

Y1 - 2013/2/20

N2 - Infection with influenza virus is a major public health problem, causing serious illness and death each year. Emergence of drug-resistant influenza virus strains limits the effectiveness of drug treatment. Importantly, a dual H275Y/I223R mutation detected in the pandemic influenza A 2009 virus strain results in multidrug resistance to current neuraminidase (NA) drugs. Therefore, discovery of new agents for treating multiple drug-resistant (MDR) influenza virus infections is important. Here, we propose a parallel screening strategy that simultaneously screens wild-type (WT) and MDR NAs, and identifies inhibitors matching the subsite characteristics of both NA-binding sites. These may maintain their potency when drug-resistant mutations arise. Initially, we analyzed the subsite of the dual H275Y/I223R NA mutant. Analysis of the site-moiety maps of NA protein structures show that the mutant subsite has a relatively small volume and is highly polar compared with the WT subsite. Moreover, the mutant subsite has a high preference for forming hydrogen-bonding interactions with polar moieties. These changes may drive multidrug resistance. Using this strategy, we identified a new inhibitor, Remazol Brilliant Blue R (RB19, an anthraquinone dye), which inhibited WT NA and MDR NA with IC50 values of 3.4 and 4.5 μM, respectively. RB19 comprises a rigid core scaffold and a flexible chain with a large polar moiety. The former interacts with highly conserved residues, decreasing the probability of resistance. The latter forms van der Waals contacts with the WT subsite and yields hydrogen bonds with the mutant subsite by switching the orientation of its flexible side chain. Both scaffolds of RB19 are good starting points for lead optimization. The results reveal a parallel screening strategy for identifying resistance mechanisms and discovering anti-resistance neuraminidase inhibitors. We believe that this strategy may be applied to other diseases with high mutation rates, such as cancer and human immunodeficiency virus type 1.

AB - Infection with influenza virus is a major public health problem, causing serious illness and death each year. Emergence of drug-resistant influenza virus strains limits the effectiveness of drug treatment. Importantly, a dual H275Y/I223R mutation detected in the pandemic influenza A 2009 virus strain results in multidrug resistance to current neuraminidase (NA) drugs. Therefore, discovery of new agents for treating multiple drug-resistant (MDR) influenza virus infections is important. Here, we propose a parallel screening strategy that simultaneously screens wild-type (WT) and MDR NAs, and identifies inhibitors matching the subsite characteristics of both NA-binding sites. These may maintain their potency when drug-resistant mutations arise. Initially, we analyzed the subsite of the dual H275Y/I223R NA mutant. Analysis of the site-moiety maps of NA protein structures show that the mutant subsite has a relatively small volume and is highly polar compared with the WT subsite. Moreover, the mutant subsite has a high preference for forming hydrogen-bonding interactions with polar moieties. These changes may drive multidrug resistance. Using this strategy, we identified a new inhibitor, Remazol Brilliant Blue R (RB19, an anthraquinone dye), which inhibited WT NA and MDR NA with IC50 values of 3.4 and 4.5 μM, respectively. RB19 comprises a rigid core scaffold and a flexible chain with a large polar moiety. The former interacts with highly conserved residues, decreasing the probability of resistance. The latter forms van der Waals contacts with the WT subsite and yields hydrogen bonds with the mutant subsite by switching the orientation of its flexible side chain. Both scaffolds of RB19 are good starting points for lead optimization. The results reveal a parallel screening strategy for identifying resistance mechanisms and discovering anti-resistance neuraminidase inhibitors. We believe that this strategy may be applied to other diseases with high mutation rates, such as cancer and human immunodeficiency virus type 1.

UR - http://www.scopus.com/inward/record.url?scp=84874225444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874225444&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0056704

DO - 10.1371/journal.pone.0056704

M3 - Article

C2 - 23437217

AN - SCOPUS:84874225444

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e56704

ER -